Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3Active not recruiting 2Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Lymphoid 2Plasma cell 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 151Leukemia 138Leukemia, Myeloid, Acute 127Myelodysplastic Syndromes 106Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma 87Lymphoma, Non-Hodgkin 86Multiple Myeloma 84Hodgkin Disease 81Lymphoma, Mantle-Cell 71Lymphoma, Follicular 68Lymphoma, Large B-Cell, Diffuse 60Congenital Abnormalities 59Myeloproliferative Disorders 58Lymphoma, B-Cell, Marginal Zone 58Leukemia, Myeloid, Chronic-Phase 56Leukemia, Myelomonocytic, Chronic 52Leukemia, Myeloid, Accelerated Phase 50Burkitt Lymphoma 50Leukemia, Myelogenous, Chronic, BCR-ABL Positive 46Lymphoma, Large-Cell, Immunoblastic 43Anemia, Refractory, with Excess of Blasts 42Waldenstrom Macroglobulinemia 41Blast Crisis 40Primary Myelofibrosis 38Melanoma 35Recurrence 34Neoplasms, Plasma Cell 34Dendritic Cell Sarcoma, Interdigitating 30Lymphoma, T-Cell, Cutaneous 29

Interventions

Cytarabine 9fludarabine 5Imatinib Mesylate 5thymoglobulin 3fludarabine phosphate 3Tacrolimus 3Sirolimus 3Methotrexate 3Cyclophosphamide 3Busulfan 3Azacitidine 3zosuquidar trihydrochloride 2venetoclax 2ponatinib 2nilotinib 2enasidenib 2bosutinib 2RO6839921 2Mycophenolic Acid 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Etoposide 2Behavior Therapy 2Antilymphocyte Serum 24-methyl-N-(3-(4-methylimidazol-1-yl)-5-trifluoromethylphenyl)-3-(4-pyrazin-2-ylpyrimidin-2-ylamino)benzamide 2spartalizumab 1sabatolimab 1quizartinib 1plerixafor 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Leukemia, Myeloid × fludarabine phosphate × Clear all
NCT01760655 2025-10-30

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Thomas Jefferson University

Phase 2 Completed
62 enrolled 15 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Leukemia, Myeloid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Polycythemia Vera, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Primary Myelofibrosis

NCT04714372 2024-10-24

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

Masonic Cancer Center, University of Minnesota

Phase 1 Completed
9 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Leukemia, Myeloid, Acute

NCT01861002 2021-06-09

A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1 Completed
15 enrolled 10 charts
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Myeloid, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡